Patients with psoriasis and/or receiving treatment for psoriasis have an increased risk of cancer.8, 9, 49, 84 Inhibitors of IL‐12/23 and IL‐23 are effective treatment approaches for psoriasis.36, 38 Existing data provide evidence to support an association between impaired IL‐12 and/or IL‐23 signalling and both tumor growth and resistance to tumor growth, although the nature of these relationships is not fully understood. Here, IL23A is linked to psoriasis.